WO1998001555A3 - Truncated soluble tumor necrosis factor type-i and type-ii receptors - Google Patents

Truncated soluble tumor necrosis factor type-i and type-ii receptors Download PDF

Info

Publication number
WO1998001555A3
WO1998001555A3 PCT/US1997/012244 US9712244W WO9801555A3 WO 1998001555 A3 WO1998001555 A3 WO 1998001555A3 US 9712244 W US9712244 W US 9712244W WO 9801555 A3 WO9801555 A3 WO 9801555A3
Authority
WO
WIPO (PCT)
Prior art keywords
type
tumor necrosis
necrosis factor
receptors
soluble tumor
Prior art date
Application number
PCT/US1997/012244
Other languages
French (fr)
Other versions
WO1998001555A2 (en
Inventor
Eric F Fischer
Carl K Edwards
Gary L Kieft
Original Assignee
Amgen Inc
Eric F Fischer
Carl K Edwards
Gary L Kieft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EA199900095A priority Critical patent/EA003900B1/en
Application filed by Amgen Inc, Eric F Fischer, Carl K Edwards, Gary L Kieft filed Critical Amgen Inc
Priority to JP50536998A priority patent/JP2002514048A/en
Priority to EP97932603A priority patent/EP0914431B1/en
Priority to NZ333647A priority patent/NZ333647A/en
Priority to SK15-99A priority patent/SK1599A3/en
Priority to DE69737814T priority patent/DE69737814T2/en
Priority to AU36013/97A priority patent/AU3601397A/en
Priority to ES97932603T priority patent/ES2288304T3/en
Priority to BR9710350A priority patent/BR9710350A/en
Priority to CA2259156A priority patent/CA2259156C/en
Priority to IL12787497A priority patent/IL127874A0/en
Publication of WO1998001555A2 publication Critical patent/WO1998001555A2/en
Publication of WO1998001555A3 publication Critical patent/WO1998001555A3/en
Priority to PL97331240A priority patent/PL189309B1/en
Priority to NO990086A priority patent/NO990086L/en
Priority to AU11121/01A priority patent/AU774307B2/en
Priority to US09/882,735 priority patent/US6989147B2/en
Priority to US11/126,126 priority patent/US7732587B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0325—Animal model for autoimmune diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Environmental Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)

Abstract

Disclosed are novel proteins, referred to as tumor necrosis factor binding proteins, that modulate the activity of tumor necrosis factor. Also disclosed are processes for obtaining the tumor necrosis binding proteins by recombinant genetic engineering techniques.
PCT/US1997/012244 1996-07-09 1997-07-09 Truncated soluble tumor necrosis factor type-i and type-ii receptors WO1998001555A2 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
ES97932603T ES2288304T3 (en) 1996-07-09 1997-07-09 TYPE I RECEPTORS OF THE TRUNCATED AND SOLUBLE TUMOR NECROSIS FACTOR.
AU36013/97A AU3601397A (en) 1996-07-09 1997-07-09 Truncated soluble tumor necrosis factor type-i and type-ii receptors
JP50536998A JP2002514048A (en) 1996-07-09 1997-07-09 Truncated soluble tumor necrosis factor type I and type II receptors
EP97932603A EP0914431B1 (en) 1996-07-09 1997-07-09 Truncated soluble tumor necrosis factor type-i receptors
NZ333647A NZ333647A (en) 1996-07-09 1997-07-09 Truncated soluble tumor necrosis factor type-I and type-II receptors
SK15-99A SK1599A3 (en) 1996-07-09 1997-07-09 Truncated soluble tumor necrosis factor type-i and type-ii receptors
DE69737814T DE69737814T2 (en) 1996-07-09 1997-07-09 SHORTEN SOLUBLE TYPE I RECIPES FOR TUMOR NEKROSE FACTOR
EA199900095A EA003900B1 (en) 1996-07-09 1997-07-09 Truncated tumor necrosis factor receptors, pharmaceutical composition on their base and methods os use of said factors and compositions
IL12787497A IL127874A0 (en) 1996-07-09 1997-07-09 Truncated soluble tumor necrosis factor type-I and type-II receptors
CA2259156A CA2259156C (en) 1996-07-09 1997-07-09 Truncated soluble tumor necrosis factor type-i and type-ii receptors
BR9710350A BR9710350A (en) 1996-07-09 1997-07-09 Stnfr truncated tumor necrosis-binding protein and polyvalent polynucleotide nucleic acid sequence polynucleotide vector c-cell procardiotic host pharmaceutical composition processes for silvering a disease mediated by tnf e to prepare a pharmaceutical composition using the tumor necrosis factor binding protein and kit
PL97331240A PL189309B1 (en) 1996-07-09 1999-01-05 Cut off soluble tumour necrosis factor receptors of i and ii type
NO990086A NO990086L (en) 1996-07-09 1999-01-08 Abbreviated, deleterious type I and type II tumor necrosis factor receptors
AU11121/01A AU774307B2 (en) 1996-07-09 2001-01-08 Truncated soluble tumor necrosis factor type-1 and type-11 receptors
US09/882,735 US6989147B2 (en) 1996-07-09 2001-06-15 Truncated soluble tumor necrosis factor type-I and type-II receptors
US11/126,126 US7732587B2 (en) 1996-07-09 2005-05-10 Nucleic acids encoding truncated soluble tumor necrosis factor

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US2144396P 1996-07-09 1996-07-09
US60/021,443 1996-07-09
US3253496P 1996-12-06 1996-12-06
US60/032,534 1996-12-06
US3773797P 1997-01-23 1997-01-23
US60/037,737 1997-01-23
US3931497P 1997-02-07 1997-02-07
US60/039,314 1997-02-07
US3979297P 1997-03-04 1997-03-04
US60/039,792 1997-03-04

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09214613 A-371-Of-International 1997-07-19
US09/882,735 Continuation US6989147B2 (en) 1996-07-09 2001-06-15 Truncated soluble tumor necrosis factor type-I and type-II receptors

Publications (2)

Publication Number Publication Date
WO1998001555A2 WO1998001555A2 (en) 1998-01-15
WO1998001555A3 true WO1998001555A3 (en) 1998-05-22

Family

ID=27533913

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/012244 WO1998001555A2 (en) 1996-07-09 1997-07-09 Truncated soluble tumor necrosis factor type-i and type-ii receptors

Country Status (22)

Country Link
US (2) US6989147B2 (en)
EP (1) EP0914431B1 (en)
JP (2) JP2002514048A (en)
KR (1) KR20000023695A (en)
AT (1) ATE364695T1 (en)
AU (2) AU3601397A (en)
BG (1) BG64910B1 (en)
BR (1) BR9710350A (en)
CA (1) CA2259156C (en)
CZ (1) CZ296835B6 (en)
DE (1) DE69737814T2 (en)
EA (1) EA003900B1 (en)
ES (1) ES2288304T3 (en)
IL (1) IL127874A0 (en)
NO (1) NO990086L (en)
NZ (1) NZ333647A (en)
PL (1) PL189309B1 (en)
SK (1) SK1599A3 (en)
TR (1) TR199700610A2 (en)
TW (1) TW555765B (en)
WO (1) WO1998001555A2 (en)
YU (1) YU299A (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7005413B1 (en) * 1995-12-22 2006-02-28 Amgen Inc. Combination therapy for conditions leading to bone loss
WO1998024477A1 (en) 1996-12-06 1998-06-11 Amgen Inc. Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
ES2284203T5 (en) 1997-04-16 2016-03-11 Amgen Inc. Osteoprotegerin binding proteins and their receptors
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
DE60024636T2 (en) * 1999-06-21 2006-08-17 Santen Pharmaceutical Co., Ltd MEDICINAL PRODUCTS FOR RHEUMATOID ARTHRITIS
WO2001058953A2 (en) 2000-02-11 2001-08-16 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
US7087224B2 (en) * 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
US7341995B2 (en) * 2000-12-06 2008-03-11 Laboratoires Serono Sa Use of SARP-1 for the treatment and/or prevention of scleroderma
DK2270052T3 (en) 2001-06-26 2018-07-02 Amgen Inc Antibodies to OPGL
MXPA04009681A (en) 2002-04-05 2005-01-11 Amgen Inc Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors.
US20040002451A1 (en) 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
WO2004098595A1 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag COMPOSITION COMPRISING ROFLUMILAST AND A TNFα ANTAGONIST
EP1718304A1 (en) * 2004-02-20 2006-11-08 Boehringer Ingelheim International GmbH Pharmaceutical compositions based on anticholinergics and pegsunercept
AU2005267722B2 (en) 2004-08-04 2009-10-08 Amgen Inc. Antibodies to Dkk-1
MX2007015476A (en) 2005-06-14 2008-02-25 Amgen Inc Self-buffering protein formulations.
TW200736277A (en) 2005-11-14 2007-10-01 Amgen Inc RANKL antibody-PTH/PTHrP chimeric molecules
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
WO2009009186A2 (en) 2007-04-13 2009-01-15 The Regents Of The University Of California Receptors useful for gas phase chemical sensing
PT2188313T (en) 2007-08-21 2017-12-12 Amgen Inc Human c-fms antigen binding proteins
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
TWI388570B (en) 2008-07-23 2013-03-11 Hanmi Science Co Ltd A polypeptide complex comprising non-peptidyl polymer having three functional ends
EP2492281B1 (en) * 2009-10-19 2018-04-11 HanAll Biopharma Co., Ltd. Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same
JP5743234B2 (en) 2010-01-15 2015-07-01 キリン−アムジェン・インコーポレーテッド Antibody formulations and treatment regimens
KR101273893B1 (en) 2010-09-13 2013-06-14 한올바이오파마주식회사 Modified human tumor necrosis factor receptor-1 polypeptides or fragments thereof and method for preparing the same
US8754037B2 (en) 2010-12-23 2014-06-17 Hanall Biopharma Co., Ltd. Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same
TW201605896A (en) 2013-08-30 2016-02-16 安美基股份有限公司 GITR antigen binding proteins
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
EP3250219A4 (en) * 2015-01-28 2018-10-03 DNX Biotech, LLC Compositions and methods of using a soluble tnf-alpha receptor modified for increased half-life
JP6976265B2 (en) 2016-03-08 2021-12-08 ヤンセン バイオテツク，インコーポレーテツド GITR antibody, method, and use
CN114917185B (en) 2016-10-21 2023-11-14 美国安进公司 Pharmaceutical formulations and methods of making the same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0398327A1 (en) * 1989-05-18 1990-11-22 Yeda Research And Development Company Limited Tumor necrosis factor binding protein II, its purification and antibodies thereto
EP0433900A1 (en) * 1989-12-13 1991-06-26 Yeda Research And Development Company Limited Expression of the recombinant tumor necrosis factor binding protein I (TBP-I)
WO1992007076A1 (en) * 1990-10-18 1992-04-30 The Mathilda And Terence Kennedy Institute Of Rheumatology Modified human tnfalpha (tumor necrosis factor alpha) receptor
WO1992016221A1 (en) * 1991-03-15 1992-10-01 Synergen, Inc. Pegylation of polypeptides

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
IN150740B (en) 1978-11-24 1982-12-04 Hoffmann La Roche
US4760067A (en) 1979-08-15 1988-07-26 Merck & Co., Inc. Allylsulfoxide enzyme inhibitors
EP0040506B1 (en) 1980-05-21 1986-08-20 Teijin Limited Reactive polymer and process for the preparation thereof
US4560649A (en) 1981-10-15 1985-12-24 Cornell Research Foundation Assaying for hLH or hCG with immobilized hormone receptors
JPH0751511B2 (en) 1982-03-15 1995-06-05 味の素株式会社 Cancer therapeutic agent containing interleukin-2
DE3378250D1 (en) 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
US4587046A (en) 1982-05-18 1986-05-06 The Regents Of The University Of California Drug-carrier conjugates
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4966888A (en) 1985-07-08 1990-10-30 Cornell Research Foundation, Inc. hCG-hLH receptor and hCG-hLH receptor-hCG complex as antigens, antibodies thereto and contraceptive vaccine
US4522750A (en) 1984-02-21 1985-06-11 Eli Lilly And Company Cytotoxic compositions of transferrin coupled to vinca alkaloids
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
SE470099B (en) 1984-05-17 1993-11-08 Jerker Porath Sulfone activated thioether adsorbents for separation of eg protein
US4578335A (en) 1984-05-21 1986-03-25 Immunex Corporation Interleukin 2 receptor
CA1283661C (en) 1984-06-20 1991-04-30 Franz Jansen Imidazolides, process for their preparation and application as intermediates for the synthesis of cytotoxic conjugates
US4675285A (en) 1984-09-19 1987-06-23 Genetics Institute, Inc. Method for identification and isolation of DNA encoding a desired protein
SE454885B (en) 1984-10-19 1988-06-06 Exploaterings Ab Tbf POLYMER COATED PARTICLES WITH IMMOBILIZED METAL ZONES IN ITS SURFACE PROCEDURES FOR PRODUCING THEREOF
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
EP0229108B1 (en) 1985-06-26 1990-12-27 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
JPS62185029A (en) 1986-02-07 1987-08-13 Ajinomoto Co Inc Modified interleukin-2
CA1283046C (en) 1986-05-29 1991-04-16 Nandini Katre Tumor necrosis factor formulation
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
IN165717B (en) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4931544A (en) 1986-09-04 1990-06-05 Cetus Corporation Succinylated interleukin-2 for pharmaceutical compositions
IL80005A (en) 1986-09-10 1992-11-15 Yeda Res & Dev Compositions for modulating the effect of tnf and il-1
US4965271A (en) 1986-12-31 1990-10-23 Hoechst Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
US5359032A (en) 1987-08-26 1994-10-25 Biogen Inc. Interkeukin-1 inhibitor
IL90339A (en) 1989-05-18 1996-10-16 Yeda Res & Dev Anti-cytotoxic protein and its purification
IL98078A0 (en) 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US5512544A (en) 1987-09-13 1996-04-30 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising an anticytokine
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5153265A (en) 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
GB8806339D0 (en) 1988-03-17 1988-04-13 Hoffmann La Roche Monoclonal antibodies
GB8807803D0 (en) 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
IL89790A (en) 1988-04-01 2002-05-23 Johns Hopking University Nucleic acid sequences that encode and cells that produce cr1 protein and methods of production and purification
US5256642A (en) 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
US5214131A (en) 1988-05-06 1993-05-25 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, modified peptides and production thereof
KR0148009B1 (en) 1988-05-27 1998-08-01 그래고리 비. 아보트 Interleukin-1 inhibitors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
JPH0240399A (en) 1988-07-27 1990-02-09 Takeda Chem Ind Ltd Complex or composition of fibroblast cell growth factor mutein
IL95064A0 (en) * 1990-07-12 1991-06-10 Yeda Res & Dev Molecular cloning of tnf binding protein
US5811261A (en) 1988-09-12 1998-09-22 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein I (TBP-I)
US5359037A (en) 1988-09-12 1994-10-25 Yeda Research And Development Co. Ltd. Antibodies to TNF binding protein I
IL94039A (en) 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
GB8824592D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Purification process
US5681566A (en) 1988-10-24 1997-10-28 3I Research Exploitation Limited Antibody conjugates with two or more covalently linked FC regions
GB8824869D0 (en) 1988-10-24 1988-11-30 Stevenson G T Synthetic antibody
US5162430A (en) 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
AU4660789A (en) 1988-11-23 1990-06-12 Genentech Inc. Polypeptide derivatives
KR910700242A (en) 1988-12-22 1991-03-14 마틴 골드스타인 Interference binders and methods
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
EP0386289A1 (en) 1989-03-07 1990-09-12 Taniguchi, Tadatsugu, Dr. Recombinant interleukin-2 receptor
US5198359A (en) 1989-03-07 1993-03-30 Boehringer Ingelheim International Gmbh Recombinant protein receptor for il-2
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US7264944B1 (en) * 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
JPH03164179A (en) * 1989-04-21 1991-07-16 Boehringer Ingelheim Internatl Gmbh Tnf receptor, tnf binding protein and dna for coding said receptor and protein
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
ES2238070T3 (en) * 1989-04-21 2005-08-16 Amgen Inc. TNF RECEPTOR, TNF BINDING PROTEIN AND CODANT DNA FOR THESE.
DE3922089A1 (en) 1989-05-09 1990-12-13 Basf Ag NEW PROTEINS AND THEIR PRODUCTION
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
IL95031A (en) * 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
NZ235148A (en) 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
CA2065346C (en) 1989-09-05 2005-03-29 Craig A. Smith Tumor necrosis factor-.alpha. and-.beta. receptors
DE59010933D1 (en) 1989-09-12 2003-05-08 Hoffmann La Roche TFN-binding proteins
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5234903A (en) 1989-11-22 1993-08-10 Enzon, Inc. Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute
DK0502956T3 (en) 1989-11-29 1997-10-20 Amgen Boulder Inc Preparation of a Recombinant Human Interleukin-1 Inhibitor.
US5136021A (en) 1990-02-27 1992-08-04 Health Research, Inc. TNF-inhibitory protein and a method of production
US5171264A (en) 1990-02-28 1992-12-15 Massachusetts Institute Of Technology Immobilized polyethylene oxide star molecules for bioapplications
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
GB2246569A (en) 1990-06-15 1992-02-05 Charing Cross Sunley Research Tumour necrosis factor - alpha binding protein
WO1992001002A1 (en) 1990-07-11 1992-01-23 Teijin Limited Tumor necrosis factor activity inhibitor and production thereof
GB9015908D0 (en) 1990-07-19 1990-09-05 Celltech Ltd Multivalent immunoglobulin
CA2087163A1 (en) 1990-07-20 1992-01-21 Hubert Agback Heterobifunctional reagents and conjugates with oxaalkylene units for amphiphilic bridge structures
EP0801082B1 (en) 1990-08-31 2003-04-09 Regents Of The University Of Minnesota Method for making graft resins for solid-phase peptide synthesis
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
AU1235692A (en) 1991-01-18 1992-08-27 Synergen, Inc. Methods for treating tumor necrosis factor mediated diseases
ES2194838T3 (en) 1991-02-27 2003-12-01 Micromet Ag PEPTIDIC BINDERS RICH IN SERINA.
CA2101918A1 (en) 1991-03-18 1992-09-19 Samuel Zalipsky Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
CA2112992C (en) 1991-07-04 2002-06-11 Allan O. F. Lihme Water-soluble, polymer-based reagents and conjugates comprising moieties derived from divinyl sulfone
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5569779A (en) 1991-12-23 1996-10-29 Albemarle Corporation Polyfunctional michael addition products
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
WO1994001483A1 (en) 1992-07-02 1994-01-20 Collagen Corporation Biocompatible polymer conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
NZ256293A (en) 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
EP0622394A1 (en) 1993-04-30 1994-11-02 S.A. Laboratoires S.M.B. Reversible modification of sulfur-containing molecules with polyalkylene glycol derivatives and their use
PT710121E (en) 1993-07-30 2001-04-30 Kennedy Inst Of Rheumatology T METHOD FOR THE TREATMENT OF MULTIPLE SCLEROSIS
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
WO1996003141A1 (en) * 1994-07-22 1996-02-08 F. Hoffmann-La Roche Ag Pharmaceutical compositions comprising a chimaeric tnf binding protein
DE4441446A1 (en) * 1994-11-22 1996-05-23 Ulrich Theis Method for transferring laundry items and preferably a trough shortage serving to carry out the method
TW313568B (en) 1994-12-20 1997-08-21 Hoffmann La Roche
US7429646B1 (en) * 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US5747639A (en) 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0398327A1 (en) * 1989-05-18 1990-11-22 Yeda Research And Development Company Limited Tumor necrosis factor binding protein II, its purification and antibodies thereto
EP0433900A1 (en) * 1989-12-13 1991-06-26 Yeda Research And Development Company Limited Expression of the recombinant tumor necrosis factor binding protein I (TBP-I)
WO1992007076A1 (en) * 1990-10-18 1992-04-30 The Mathilda And Terence Kennedy Institute Of Rheumatology Modified human tnfalpha (tumor necrosis factor alpha) receptor
WO1992016221A1 (en) * 1991-03-15 1992-10-01 Synergen, Inc. Pegylation of polypeptides

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BANNER D.W. ET AL.: "Crystal structure of the soluble human 55 kd TNF receptor-human TNF-beta complex: implications for the TNF receptor activation", CELL, vol. 73, 7 May 1993 (1993-05-07), pages 431 - 445, XP002047951 *
CHIH-HSUEH CHEN P. ET AL.: "Mapping the domain(s) critical for the binding of human tumor necrosis factor-alpha to its two receptors", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 6, 10 February 1995 (1995-02-10), pages 2874 - 2878, XP002047953 *
FU Z.-Q.: "Model complexes of tumor necrosis factor-alpha with receptors R1 and R2", PROTEIN ENGINEERING, vol. 8, no. 12, 1995, pages 1233 - 1241, XP002057955 *
MARSTERS S.A. ET AL.: "Identification of cystein-rich domains of the type 1 tumor necrosis factor receptor involved in ligand binding", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, no. 9, 25 March 1992 (1992-03-25), pages 5747 - 5750, XP002047952 *

Also Published As

Publication number Publication date
PL189309B1 (en) 2005-07-29
DE69737814D1 (en) 2007-07-26
ES2288304T3 (en) 2008-01-01
AU3601397A (en) 1998-02-02
CZ296835B6 (en) 2006-06-14
US20050250696A1 (en) 2005-11-10
NO990086D0 (en) 1999-01-08
CA2259156C (en) 2010-09-07
JP2009280612A (en) 2009-12-03
DE69737814T2 (en) 2008-03-06
AU774307B2 (en) 2004-06-24
TR199700610A3 (en) 1998-01-21
CA2259156A1 (en) 1998-01-15
EA003900B1 (en) 2003-10-30
KR20000023695A (en) 2000-04-25
YU299A (en) 1999-11-22
NO990086L (en) 1999-03-09
TR199700610A2 (en) 1998-01-21
ATE364695T1 (en) 2007-07-15
BG103091A (en) 2000-05-31
PL331240A1 (en) 1999-07-05
CZ499A3 (en) 2000-01-12
JP2002514048A (en) 2002-05-14
SK1599A3 (en) 2001-02-12
EA199900095A1 (en) 2000-02-28
BR9710350A (en) 1999-08-17
US7732587B2 (en) 2010-06-08
BG64910B1 (en) 2006-08-31
US20030054439A1 (en) 2003-03-20
US6989147B2 (en) 2006-01-24
EP0914431B1 (en) 2007-06-13
EP0914431A2 (en) 1999-05-12
TW555765B (en) 2003-10-01
IL127874A0 (en) 1999-10-28
AU1112101A (en) 2001-04-05
WO1998001555A2 (en) 1998-01-15
NZ333647A (en) 2000-09-29

Similar Documents

Publication Publication Date Title
WO1998001555A3 (en) Truncated soluble tumor necrosis factor type-i and type-ii receptors
BG104149A (en) Interleukin-18-binding proteins, methods for their preparation and administration
IL130190A0 (en) Methods and compositions for polypeptide engineering
ZA9710098B (en) Halogenopyrimidines.
AU1750097A (en) Highly concentrated, lyophilized, and liquid factor ix formulations
BR0013231A (en) Multiple cytokine-antibody complexes
EP2016953A3 (en) Vascular endothelial cell growth factor antagonists and uses thereof
HK1109423A1 (en) Apo-2 receptor apo-2
EP1073465A4 (en) T cell inhibitory receptor compositions and uses thereof
EP0679093A1 (en) Methods of delivering agents to target cells.
MX9600666A (en) Protocadherin proteins and their uses.
AU4815197A (en) Tetraphosphonate bicyclic trisanhydrides
WO1999002552A3 (en) Chimeric interleukin-6 soluble receptor/ligand protein, analogs thereof and uses thereof
AU1207301A (en) Stabilized proteins
AU7471698A (en) Intracellular production of hepatitis c e1 and e2 truncated polypeptides
GR3036782T3 (en) Proteases capable of shedding the soluble TNF-receptor and TNF-R derived peptides and antibodies against the proteases inhibiting the shedding.
AU2130697A (en) Recombinant ribonuclease proteins
WO2001019861A3 (en) Apo-2 receptor antibodies
WO1993015203A3 (en) Polypeptides with fibronectin binding sites as modulators for matrix assembly
AU3711597A (en) A novel galanin receptor
WO2004089973A3 (en) Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
AU3651997A (en) Constructs and complexes of cyclin e
WO1998028419A3 (en) Methods and compositions for modulation of vesicular release
BG103627A (en) New ifn receptor 1-binding proteins, dna encoding them, and methods for the modulation of a cellular response for interferons
WO2003091397A3 (en) Methods and compositions for regulating cellular signaling

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97197728.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PV1999-4

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2259156

Country of ref document: CA

Ref document number: 2259156

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 333647

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/000364

Country of ref document: MX

Ref document number: 1599

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 1997932603

Country of ref document: EP

Ref document number: 09214613

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1019997000152

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 199900095

Country of ref document: EA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997932603

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1999-4

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019997000152

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1019997000152

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: PV1999-4

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 1997932603

Country of ref document: EP